GeneArt™ Genomic Cleavage Detection Kit
GeneArt™ Genomic Cleavage Detection Kit
Invitrogen™

GeneArt™ Genomic Cleavage Detection Kit

The GeneArt Genomic Cleavage Detection Kit is a fast, T7 endonuclease I based method to quantify how well your genomeRead more
Have Questions?
Catalog NumberQuantity
A2437220 reactions
Catalog number A24372
Price (USD)
261.65
Online Exclusive
276.00
Save 14.35 (5%)
Each
In stock
Add to cart
Quantity:
20 reactions
Recurring order eligible. Learn more »
Price (USD)
261.65
Online Exclusive
276.00
Save 14.35 (5%)
Each
Add to cart
Ask our AI about this Product
The GeneArt Genomic Cleavage Detection Kit is a fast, T7 endonuclease I based method to quantify how well your genome editing protocol causes insertions and deletions (indels) in the genome of your cell line. This is the quickest way to quantify and validate the best CRISPR-Cas9 gRNA, or the best TAL effector nuclease, for your cell engineering experiment. The GeneArt Genomic Cleavage Detection Kit provides a convenient, quick, and complete solution.

Using this T7 endonuclease I (T7EI) based method, you can quickly and confidently measure your on-target genome editing efficiency generated by non-homologous end joining (NHEJ) activity. The advantages of the GeneArt Genomic Cleavage Detection Kit are:

Minimal hands-on time — PCR amplify from cell lysate, no DNA purification required
Short protocol — four hours from cell harvest to quantified results
Just add PCR primers — everything needed in one box. No separate PCR master mixes or DNA extraction kits to buy.
Quantify editing efficiency directly from your gel — gel band density directly correlates to on-target indel formation

Obtain results the same day without waiting for sequencing results or performing complicated sequencing analysis.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
FormatKit
No. of Reactions20 Reactions
PolymeraseTaq Polymerase
Product TypeGenomic Cleavage Detection Kit
Quantity20 reactions
Recognition SiteINDEL
Sufficient For20 Reactions
TechniqueCRISPR-Cas9, TAL Effector Nuclease
Detection MethodPrimer-probe
FormLiquid
Reaction SpeedFast
Unit SizeEach
Contents & Storage
Contains:

• 1 bottle Cell Lysis Buffer
• 1 tube Proteinase K
• 1 tube PCR Supermix
• 1 tube Water
• 1 tube T7E1 Detection Enzyme
• 1 tube T7E1 Detection Reaction Buffer
• 1 tube Control Template & Primers

Store all components at -5° to -30°C.
Have questions about this product? Ask our AI assisted search.
Is it possible to use CRISPR-Cas technology for prokaryotic gene engineering?
Are TAL-meditated KO or KI strains considered GMO (genetically modified organisms)?
How does the GeneArt Genomic Cleavage Detection Kit work?
What vectors are offered with the Invitrogen GeneArt PerfectMatch TALS?
Do you have primer design recommendations when working with the Invitrogen GeneArt Genomic Cleavage Detection Kit?
+Show more FAQs for this product
This is an AI-powered search and may not always get things right. You can help us make it better with a thumbs up or down on individual answers or by selecting the “Give feedback" button. Your search history and customer login information may be retained by Thermo Fisher and processed in accordance with our Privacy Notice.

Frequently asked questions (FAQs)

What are TALs or TALENS?

TALs or TALENs are transcription activator-like effector nuclease proteins that are naturally occurring transcriptional activators secreted by Xanthomonas spp. into their plant hosts. GeneArt TALs are derived from Xathomonas TAL effectors, the DNA-binding domain of which consists of a variable number of amino acid repeats. Each repeat contains 33–35 amino acids and recognizes a single DNA base pair. The DNA recognition occurs via 2 hypervariable amino acid residues at positions 12 and 13 within each repeat, called repeat-variable di-residues (RVDs). TAL effector repeats can be assembled in modular fashion, varying the RVDs to create a TAL protein that recognizes a specific target DNA sequence.

What is CRISPR-STOP?

CRISPR-STOP is a method of inserting STOP codon sequences to generate knockouts.

Please refer to the following article: CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations.

Find additional tips, troubleshooting help, and resources within our Genome Editing Support Center.

I am working with TALs and want to incorporate an effector domain that you do not carry. What should I do?

We do offer a multiple cloning site sequence in the place of the effector domain sequence for our TAL MCS entry vector. This option allows you to insert any protein-coding sequence, and allows your resulting TAL protein to deliver the effector in a sequence-specific manner anywhere in the genome. We also provide gene synthesis services to generate any effector domain for which you don't have a template.

I am trying to design my TAL but do not have a T at the 5´ end of the TAL effector. What should I do?

While our Invitrogen GeneArt Precision TALs required a T at the 5´end and 13-18 bp spacing between the forward and reverse TAL effectors for proper pairing of Fok1 nucleases, the Invitrogen GeneArt PerfectMatch TALs allow for targeting of any sequence across the genome and eliminates the 5´ T constraints. Additionally, the spacing between the two effectors is optimal at 15-16 bp.

The binding domain for TALs can be either 19 or 25 bp in length. Does one work better than the other?

The 19 bp binding domains perform better for the nucleases. The binding sites do not need to be the same size; however, best performance for the nucleases is with the 19 bp binding domains.

Figures

Videos

The Power of CRISPR Genome Editing
It’s your time to change the world. And it’s our promise to empower you with cell engineering tools and solutions that help you get results even faster. Increasing your chances of success at every step.
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Customers who viewed this item also viewed



      Documents & Downloads

      Certificates

      Lot #Certificate TypeDateCatalog Number(s)
      3177415Certificate of AnalysisJun 16, 2025A24372
      3226726Certificate of AnalysisMay 28, 2025A24372
      3155622Certificate of AnalysisMay 06, 2025A24372
      3135997Certificate of AnalysisMar 26, 2025A24372
      3098946Certificate of AnalysisMar 05, 2025A24372
      5 results displayed, search above for a specific certificate

      Safety Data Sheets

      Citations & References (7)

      Citations & References
      Abstract
      CRISPR/Cas9-Mediated Genomic Deletion of the Beta-1, 4 N-acetylgalactosaminyltransferase 1 Gene in Murine P19 Embryonal Carcinoma Cells Results in Low Sensitivity to Botulinum Neurotoxin Type C.
      Authors:Tsukamoto K, Ozeki C, Kohda T, Tsuji T,
      Journal:
      PubMed ID:26177297
      'Botulinum neurotoxins produced by Clostridium botulinum cause flaccid paralysis by inhibiting neurotransmitter release at peripheral nerve terminals. Previously, we found that neurons derived from the murine P19 embryonal carcinoma cell line exhibited high sensitivity to botulinum neurotoxin type C. In order to prove the utility of P19 cells for the ... More
      Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection.
      Authors:Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M, Carte J, Chen W, Roark N, Ranganathan S, Ravinder N, Chesnut JD,
      Journal:
      PubMed ID:26003884
      'CRISPR-Cas9 systems provide a platform for high efficiency genome editing that are enabling innovative applications of mammalian cell engineering. However, the delivery of Cas9 and synthesis of guide RNA (gRNA) remain as steps that can limit overall efficiency and ease of use. Here we describe methods for rapid synthesis of ... More
      Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system.
      Authors:Sakuma T, Nishikawa A, Kume S, Chayama K, Yamamoto T,
      Journal:
      PubMed ID:24954249
      CRISPR/Cas9-mediated genome editing is a next-generation strategy for genetic modifications, not only for single gene targeting, but also for multiple targeted mutagenesis. To make the most of the multiplexity of CRISPR/Cas9, we established a system for constructing all-in-one expression vectors containing multiple guide RNA expression cassettes and a Cas9 nuclease/nickase ... More
      Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA.
      Authors:Liang X, Potter J, Kumar S, Ravinder N, Chesnut JD
      Journal:J Biotechnol
      PubMed ID:27845164
      'While CRISPR-based gene knock out in mammalian cells has proven to be very efficient, precise insertion of genetic elements via the cellular homology directed repair (HDR) pathway remains a rate-limiting step to seamless genome editing. Under the conditions described here, we achieved up to 56% targeted integration efficiency with up ... More
      Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX.
      Authors:Yu X, Liang X, Xie H, Kumar S, Ravinder N, Potter J, de Mollerat du Jeu X, Chesnut JD,
      Journal:Biotechnol Lett
      PubMed ID:26892225
      'To identify the best lipid nanoparticles for delivery of purified Cas9 protein and gRNA complexes (Cas9 RNPs) into mammalian cells and to establish the optimal conditions for transfection. Using a systematic approach, we screened 60 transfection reagents using six commonly-used mammalian cell lines and identified a novel transfection reagent (named ... More
      7 total citations

      Other products to consider



      Share catalog number, name or link

      1x1 image pixel for data collection